Galmed Pharmaceuticals EOCN
NASDAQ EOCN
$3.61 +0.15 (+4.34%)
At close: Oct 2, 2026 · 4:00 PM EDT

Galmed Pharmaceuticals (EOCN) Asset Writedowns and Impairment (2025)

Updated

Galmed Pharmaceuticals' Asset Writedowns and Impairment was $1.97 million in Q4 2025.

Analysis

Galmed Pharmaceuticals (EOCN) Asset Writedowns and Impairment (2025) Analysis & Trends

For FY2025, Asset Writedowns and Impairment at Galmed Pharmaceuticals came in at $2.5 million, up 118.3% from FY2024.

  • In earlier years, Asset Writedowns and Impairment was $1.15 million in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Galmed Pharmaceuticals 420,034.32 420,034.32 -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.97 Mn
API Access

Galmed Pharmaceuticals Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=EOCN&period=max&api_key=YOUR_API_KEY